rxstat › Prices in Ontario › Risankizumab
Risankizumab (Skyrizi) price and coverage in Ontario
Risankizumab 150 mg/1ml solution lists at $4935.00 per billed unit in Ontario on the Ontario Drug Benefit (ODB) program's price list (Oct 30, 2026), before the pharmacy's dispensing fee.
Risankizumab is covered by the Ontario Drug Benefit (ODB) program as a regular benefit.
Price by strength in Ontario
| Strength and form | Lowest price | Brand |
|---|---|---|
| 150 mg/1ml Solution2 products · covered | $4935.00/unit | – |
| 75 mg/0.83ml Solution1 product · covered | $2467.50/unit | – |
All 3 products listed in Ontario
| Product | Price | Coverage |
|---|---|---|
| 150 mg/1ml Solution | ||
| SkyriziAbbVie Corporation · DIN 02519291 | $4935.00/unit | Covered |
| SkyriziAbbVie Corporation · DIN 02519283 | $4935.00/unit | Covered |
| 75 mg/0.83ml Solution | ||
| SkyriziAbbVie Corporation · DIN 02487454 | $2467.50/unit | Covered |
What you'll pay at the pharmacy
These are the prices the Ontario Drug Benefit (ODB) program lists for the drug itself. The pharmacy adds a dispensing fee and sometimes a markup, so paying cash costs more. If you have coverage, your share depends on your deductible and co-pay.
Shortage status
No active shortage is reported for Risankizumab in Canada. Full drug page.
Risankizumab price in other provinces
Common questions
How much does Risankizumab cost in Ontario?
Risankizumab 150 mg/1ml solution lists at $4935.00 per billed unit in Ontario on the Ontario Drug Benefit (ODB) program's price list (Oct 30, 2026), before the pharmacy's dispensing fee.
Is Risankizumab covered in Ontario?
Risankizumab is covered by the Ontario Drug Benefit (ODB) program as a regular benefit.
Is Risankizumab cheaper in another province?
For 150 mg/1ml solution, listed prices run from $4935.00 to $4935.00 across 3 provinces. Public plans only cover their own residents, though.
Source: Ontario Drug Benefit Formulary (Oct 30, 2026). Public plan list prices per unit, before pharmacy fees and markup. This page is not medical advice.